Patent ID: 11866446
Assignee: VERTEX PHARMACEUTICALS INCORPORATED
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 25:
26. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein Ra, for each occurrence, is independently selected from halogen, cyano, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, —C(═O)NRhRi, —NRhRi, —NRhC(═O)Rk, —ORk, —[O(CH2)q]rO(C1-C6 alkyl), —S(═O)2Rk, —S(═O)2NRhRi, C3-C6 cycloalkyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 8-membered heteroaryl; wherein:
the C1-C6 alkyl of Ra is optionally substituted with 1 to 3 groups independently selected from cyano, —C(═O)NRhRi, —NRhRi, —NRhC(═O)Rk, —NRhC(═O)ORk, —NRhC(═O)NRiRj,, —NRhS(═O)pRk, —ORk, —S(═O)2Rk, —S(═O)pNRhRi, and C3-C6 cycloalkyl;
the C3-C6 cycloalkyl, the 5 to 10-membered heterocyclyl, the phenyl, and the 5- to 8-membered heteroaryl of Ra are each optionally substituted with 1 to 3 groups independently selected from halogen, C1-C2 alkyl, and —ORk; wherein:
Rh, Ri, and Rj, for each occurrence, are each independently selected from hydrogen, C1-C2 alkyl, cyclopropyl, and cyclobutyl; wherein:
the C1-C2 alkyl of any one of Rh, Ri, and Rj is optionally substituted with 1 to 3 groups independently selected from halogen and —OH;

Rk, for each occurrence, are each independently selected from hydrogen and

C1-C4 alkyl; wherein:
the C1-C4 alkyl of Rk is optionally substituted with 1 to 3 groups independently selected from halogen and —OH; and

q and r are each an integer selected from 1, 2, and 3.